Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
暂无分享,去创建一个
Carol M. Mangione | Susan J. Curry | Alex R. Kemper | Karina W. Davidson | Douglas K. Owens | Ann E. Kurth | Chien-Wen Tseng | Alex H. Krist | Michael J. Barry | John W. Epling | M. Phipps | Chyke A Doubeni | M. Barry | D. Grossman | C. Mangione | D. Owens | A. Kemper | A. Krist | K. Davidson | J. Epling | S. Curry | A. Kurth | C. Landefeld | M. Silverstein | M. Simon | Chien-Wen Tseng | Michael Silverstein | C. Seth Landefeld | Melissa A. Simon | David C. Grossman | Chyke A. Doubeni | Maureen G. Phipps | Michael Silverstein
[1] B. Goff,et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. , 2004, JAMA.
[2] Mindy M Horrow,et al. ACR appropriateness criteria© ovarian cancer screening. , 2010, Ultrasound quarterly.
[3] Nikki A. Hawkins,et al. Physician characteristics and beliefs associated with use of pelvic examinations in asymptomatic women. , 2012, Preventive medicine.
[4] D. Bowen,et al. Changes in cancer worry associated with participation in ovarian cancer screening , 2007, Psycho-oncology.
[5] V. Moyer,et al. Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement , 2012, Annals of Internal Medicine.
[6] Ian J. Jacobs,et al. SCREENING FOR OVARIAN CANCER : A PILOT RANDOMISED CONTROLLED TRIAL , 1999 .
[7] J. Thigpen,et al. Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial , 2011 .
[8] B. Karlan,et al. "Ovarian cancers: Evolving paradigms in research and care": Report from the Institute of Medicine. , 2016, Gynecologic oncology.
[9] Barnett S Kramer,et al. The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications , 2017, Journal of medical screening.
[10] D. Oram,et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2016, The Lancet.
[11] J. Gohagan,et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. , 2016, Gynecologic oncology.
[12] I. Jacobs,et al. Psychological morbidity associated with ovarian cancer screening: results from more than 23 000 women in the randomised trial of ovarian cancer screening (UKCTOCS) , 2014, BJOG : an international journal of obstetrics and gynaecology.
[13] S. Fedewa,et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening , 2017, CA: a cancer journal for clinicians.
[14] L. Esserman,et al. Genetic/familial high-risk assessment , 2010 .
[15] V. Moyer. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. , 2014, Annals of internal medicine.
[16] J. Gohagan,et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.
[17] Gerhard Jentzsch,et al. Working group on , 1991 .
[18] M. Phipps,et al. Screening for Gynecologic Conditions With Pelvic Examination: US Preventive Services Task Force Recommendation Statement , 2017, JAMA.